Abstract:Abstract Abstract 3638 Background: CAG regimen (cytarabine, aclarubicin, G-CSF) has been commonly used in China and Japan for the treatment of AML and MDS. This study is to summarize the data and to analyze the efficacy as well as the toxic effects of CAG regimen in acute leukemia (AL) and MDS pts. Methods: The databases of PubMed, Wanfang Data, as well as American Society of Hematology (ASH) annual meeting abstracts were searched for articles published in English, Chinese and Japanese languages between January 1995 and December 2010. Eligible studies were relevant clinical trials on AL and MDS pts treated with CAG regimen. Complete remission (CR) rates and odds ratio (OR) were compared through a meta-analysis using a random-effects or fixed-effects model. Results: 37 trials with a total of 1045 AL and MDS pts were included for analysis. Among the 1045 pts treated with CAG, 819 pts were AML, 215 pts were de novo MDS or transformed AML (MDS/tAML), 6 pts were ALL, and 5 pts were biphenotypic acute leukemia (BAL). The AML CR rate of CAG from 29 studies was 58.0% (95% CI, 53.1%-62.7%). The MDS/t-AML CR rate from 12 studies was 45.7% (95% CI, 39.0%-52.4%). The AML CR rate was significantly better than that of MDS /tAML (Q=8.072, p<0.01). Among 819 AML pts, 327 pts were newly diagnosed, 370 pts were relapsed/refractory (R/R) AML. The AML status was not specified in the rest 122 pts. Interestingly, no significant difference in CR rates was noted between the newly diagnosed (57.0%, 95% CI 51.5%-62.3%) and R/R AML pts (60.1%, 95% CI 50.5%-68.9%) (Q=0.312, p>0.05). The CR rate for the 367 elderly AML pts was 52% (95% CI 51.5%-62.3%). The CR rate was also significantly higher in pts with favorable (64.5%, 95% CI 38.8%-83.9%) and intermediate (69.6%, 95% CI 60.4%-77.5%) cytogenetics than those with unfavorable one (29.5%, 95% CI 19.7%-41.8%) (p<0.05). There were 7 trials that compared the CR rates of CAG regimen with those of other induction regimens in AML pts. Surprisingly, the CR rate of CAG was significantly higher than those of other induction regimens (OR 2.425, 95% CI, 1.515–3.880). CAG regimens were well tolerated with cardiotoxicity in 0.42% cases (4/954) and early death occurred in 4.40% cases (44/1000). Conclusions: CAG regimen induced significantly higher CR rates in AML than in MDS pts. The CR rates of CAG regimen was significantly better than those of other induction regimens in AML pts. This regimen was well tolerated with low cardiotoxicity and early death rate. Disclosures: No relevant conflicts of interest to declare.

Clinical Study of CAG Regimen in Treating Acute Myeloid Leukemia

Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: a Multicenter Study of 112 Chinese Patients.

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Observations of Efficacy of CAG Regimen in Treatment of Relapsing, Refractory and Secondary Acute Myeloid Leukemia

Therapeutic Effect of CAG Regimen on Patients with Recurrent Acute Myelocytic Leukemia

CAG Regimen for Refractory or Relapsed Adult T-Cell Acute Lymphoblastic Leukemia: A Retrospective, Multicenter, Cohort Study

Curative Effect of CAG Regimen on Patients with Untreated Acute Myeloid Leukemia and Its Mechanism

The clinical curative effect observation of patients with acute leukemia and high risk MDS treated by CAG regimen

[The Efficacy and Safety of HAA Regimen As Induction Chemotherapy in 150 Newly Diagnosed Acute Myeloid Leukemia].

Efficacy of HAA Regimen in the Treatment of 64 Patients with Refractory/relapsed Acute Myeloid Leukemia

[Clinical Efficacies and Safety of HAG Regimen for Patients with High-Risk Myelodysplastic Syndromes: a Multicentre Study].

A Meta-Analysis of CAG (cytarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1045 Patients with Leukemia in China and Japan,

Effect of CAG induction therapy in patients with acute myeloid leukemia

A Meta-Analysis of CAG (cytarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1029 Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Cytarabine, Aclarubicin and Granulocyte Colony-Stimulating Factor Regimen Represents an Effective and Safe Salvage Regimen for Patients with Acute Myeloid Leukemia Refractory to First Course of Induction Chemotherapy

Clinical And Laboratory Study Of Cag Regimen In Treating Aml Subtypes Hard To Cure.

Efficacy of Aclacinomycin Plus Intermediate Dose of Cytarabine for Patients with Refractory and Relapsed Acute Myeloid Leukemia

Outcomes and Survival Analysis of Patients with AML and High Risk MDS Treated by CAG Regimen

Clinical Outcome of Decitabine Combined with CAG Regimen for Treatment of Acute Myeloid Leukemia Ineligible for Conventional Chemotherapy

Clinnical Study of Consisting G-CSF GAD/GMD Regimen in treating Acute Myeloid Leukemia